Mastering Organoid Growth: A Complete Guide to Overcoming Methodological Challenges

Abstract

Organoid technology has become among the most popular technologies in recent years, due to their three-dimensional and physiologically enriching models that closely mimic the structure and function of human organs. Herein, this review details the in-depth methodology, updated to date, for the efficient cultivation of organoids. Emphasizing liver organoids, both hepatocyte and cholangiocyte derived, and other abdominal organ systems, such as gut, kidney, and pancreas, we explore the technological challenges researchers are facing nowadays, including how to optimize nutrient delivery, maintain cellular diversity, achieve scalability in the organoid culture system, and high-throughput applications. Addressing those biological and technological complexities, this review aimed at equipping new researchers with practical insights and standardized protocols that will help improve reproducibility and success rates in organoid culture and expand their applications. Furthermore, we discuss current limitations and barriers to clinical translation, highlight key knowledge gaps, and outline emerging innovations, including bioengineering, microfluidic systems, and genetic manipulation, expected to further enhance disease modeling, personalized medicine, and regenerative therapies. Finally, we provide perspective on next-generation technologies that expedite organoid-based discovery and development.

Keywords

cholangiocyte / methodology / organoid / organoid applications

References

[1] E. C. Costa, A. F. Moreira, D. de Melo-Diogo, V. M. Gaspar, M. P. Carvalho, and I. J. Correia, “3D tumor Spheroids: An Overview on the Tools and Techniques Used for Their Analysis,” Biotechnology Advances 34, no. 8 (2016): 1427–1441.

[2] S. A. Langhans, “Three-dimensional in Vitro Cell Culture Models in Drug Discovery and Drug Repositioning,” Frontiers in Pharmacology 9 (2018): 6.

[3] T. S. Biju, V. V. Priya, and A. P. Francis, “Role of Three-dimensional Cell Culture in Therapeutics and Diagnostics: An Updated Review,” Drug Delivery and Translational Research 13, no. 9 (2023): 2239–2253.

[4] C. P. Soares, V. Midlej, M. E. W. D. Oliveira, M. Benchimol, M. L. Costa, and C. Mermelstein, “2D and 3D-organized Cardiac Cells Shows Differences in Cellular Morphology, Adhesion Junctions, Presence of Myofibrils and Protein Expression,” PLoS ONE 7, no. 5 (2012): e38147.

[5] J. C. Fontoura, C. Viezzer, and F. G. Dos Santos, “Comparison of 2D and 3D Cell Culture Models for Cell Growth, Gene Expression and Drug Resistance,” Materials Science & Engineering C, Materials for Biological Applications 107 (2020): 110264.

[6] M. Ravi, V. Paramesh, S. R. Kaviya, E. Anuradha, and F. D. P. Solomon, “3D cell Culture Systems: Advantages and Applications,” Journal of Cellular Physiology 230, no. 1 (2015): 16–26.

[7] Y. Imamura, T. Mukohara, Y. Shimono, et al., “Comparison of 2D- and 3D-culture Models as Drug-testing Platforms in Breast Cancer,” Oncology Reports 33, no. 4 (2015): 1837–1843.

[8] W. L. Haisler, D. M. Timm, J. A. Gage, H. Tseng, T. C. Killian, and G. R. Souza, “Three-dimensional Cell Culturing by Magnetic Levitation,” Nature Protocols 8, no. 10 (2013): 1940–1949.

[9] M. Huch, H. Gehart, R. van Boxtel, et al., “Long-Term Culture of Genome-Stable Bipotent Stem Cells From Adult Human Liver,” Cell 160, no. 1-2 (2015): 299–312.

[10] L. Broutier, A. Andersson-Rolf, C. J. Hindley, et al., “Culture and Establishment of Self-renewing human and Mouse Adult Liver and Pancreas 3D Organoids and Their Genetic Manipulation,” Nature Protocols 11, no. 9 (2016): 1724–1743.

[11] A. Sontheimer-Phelps, B. A. Hassell, and D. E. Ingber, “Modelling Cancer in Microfluidic human Organs-on-chips,” Nature Reviews Cancer 19, no. 2 (2019): 65–81.

[12] T. Ishiguro, H. Ohata, A. Sato, K. Yamawaki, T. Enomoto, and K. Okamoto, “Tumor-derived Spheroids: Relevance to Cancer Stem Cells and Clinical Applications,” Cancer Science 108, no. 3 (2017): 283–289.

[13] S. J. Mun, J. S. Ryu, M. O. Lee, et al., “Generation of Expandable human Pluripotent Stem Cell-derived Hepatocyte-Like Liver Organoids,” Journal of Hepatology 71, no. 5 (2019): 970–985.

[14] M. A. Lancaster and J. A. Knoblich, “Organogenesis in a Dish: Modeling Development and Disease Using Organoid Technologies,” Science 345, no. 6194 (2014): 1247125.

[15] M. Simian and M. J. Bissell, “Organoids: A Historical Perspective of Thinking in Three Dimensions,” Journal of Cell Biology 216, no. 1 (2017): 31–40.

[16] R. L. Reis, “2nd Consensus Conference on Definitions on Biomaterials Science,” J Tissue Eng Regen Med 14, no. 4 (2020): 561–562.

[17] H. Clevers, “Modeling Development and Disease With Organoids,” Cell 165, no. 7 (2016): 1586–1597.

[18] Y. Yamamoto, S. Gotoh, Y. Korogi, et al., “Long-term Expansion of Alveolar Stem Cells Derived From human iPS Cells in Organoids,” Nature Methods 14, no. 11 (2017): 1097–1106.

[19] A. B. Alber, H. A. Marquez, L. Ma, et al., “Directed Differentiation of Mouse Pluripotent Stem Cells Into Functional Lung-specific Mesenchyme,” Nature Communications 14, no. 1 (2023): 3488.

[20] T. Panciera, L. Azzolin, A. Fujimura, et al., “Induction of Expandable Tissue-Specific Stem/Progenitor Cells Through Transient Expression of YAP/TAZ,” Cell Stem Cell 19, no. 6 (2016): 725–737.

[21] O. C. Tysoe, A. W. Justin, T. Brevini, et al., “Isolation and Propagation of Primary human Cholangiocyte Organoids for the Generation of Bioengineered Biliary Tissue,” Nature Protocols 14, no. 6 (2019): 1884–1925.

[22] J. M. Hallett, S. Ferreira-Gonzalez, T. Y. Man, et al., “Human Biliary Epithelial Cells From Discarded Donor Livers Rescue Bile Duct Structure and Function in a Mouse Model of Biliary Disease,” Cell Stem Cell 29, no. 3 (2022): 355–371. e10.

[23] Y. Guan, A. Enejder, M. Wang, et al., “A human Multi-lineage Hepatic Organoid Model for Liver Fibrosis,” Nature Communications 12, no. 1 (2021): 6138.

[24] L. Broutier, G. Mastrogiovanni, M. M. Verstegen, et al., “Human Primary Liver Cancer–derived Organoid Cultures for Disease Modeling and Drug Screening,” Nature Medicine 23, no. 12 (2017): 1424–1435.

[25] A. L. Bredenoord, H. Clevers, and J. A. Knoblich, “Human Tissues in a Dish: The Research and Ethical Implications of Organoid Technology,” Science 355, no. 6322 (2017): eaaf9414.

[26] S. Nuciforo, I. Fofana, M. S. Matter, et al., “Organoid Models of Human Liver Cancers Derived From Tumor Needle Biopsies,” Cell reports 24, no. 5 (2018): 1363–1376.

[27] M. Kasendra, A. Tovaglieri, A. Sontheimer-Phelps, et al., “Development of a Primary human Small Intestine-on-a-Chip Using Biopsy-derived Organoids,” Scientific Reports 8, no. 1 (2018): 2871.

[28] M. van de Wetering, H. E. Francies, J. M. Francis, et al., “Prospective Derivation of a Living Organoid Biobank of Colorectal Cancer Patients,” Cell 161, no. 4 (2015): 933–945.

[29] E. Driehuis, K. Kretzschmar, and H. Clevers, “Establishment of Patient-derived Cancer Organoids for Drug-screening Applications,” Nature Protocols 15, no. 10 (2020): 3380–3409.

[30] K. Kawasaki, K. Toshimitsu, M. Matano, et al., “An Organoid Biobank of Neuroendocrine Neoplasms Enables Genotype-Phenotype Mapping,” Cell 183, no. 5 (2020): 1420–1435. e21.

[31] C. A. Rimland, S. G. Tilson, C. M. Morell, et al., “Regional Differences in Human Biliary Tissues and Corresponding in Vitro–Derived Organoids,” Hepatology 73, no. 1 (2021): 247–267.

[32] J. G. Camp, K. Sekine, T. Gerber, et al., “Multilineage Communication Regulates human Liver Bud Development From Pluripotency,” Nature 546, no. 7659 (2017): 533–538.

[33] R. R. Zhang, M. Koido, T. Tadokoro, et al., “Human iPSC-Derived Posterior Gut Progenitors Are Expandable and Capable of Forming Gut and Liver Organoids,” Stem Cell Reports 10, no. 3 (2018): 780–793.

[34] M. M. A. Verstegen, R. P. Coppes, A. Beghin, et al., “Clinical Applications of human Organoids,” Nature Medicine 31, no. 2 (2025): 409–421.

[35] J. A. Thomson, J. Itskovitz-Eldor, S. S. Shapiro, et al., “Embryonic Stem Cell Lines Derived From human Blastocysts,” Science 282, no. 5391 (1998): 1145–1147.

[36] B. Lo and L. Parham, “Ethical Issues in Stem Cell Research,” Endocrine Reviews 30, no. 3 (2009): 204.

[37] M. Rao, C. C. Liu, S. Wang, and K. C. Chang, “Generating ESC-derived RGCs for Cell Replacement Therapy,” Methods in Molecular Biology (Clifton NJ) 2848 (2025): 187–196.

[38] K. Takahashi and S. Yamanaka, “Induction of Pluripotent Stem Cells From Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors,” Cell 126, no. 4 (2006): 663–676.

[39] H. Clevers, “Modeling Development and Disease With Organoids,” Cell 165, no. 7 (2016): 1586–1597.

[40] U. Ben-David and N. Benvenisty, “The Tumorigenicity of human Embryonic and Induced Pluripotent Stem Cells,” Nature Reviews Cancer 11, no. 4 (2011): 268–277.

[41] R. Nguyen, S. Da Won Bae, L. Qiao, and J. George, “Developing Liver Organoids From Induced Pluripotent Stem Cells (iPSCs): An Alternative Source of Organoid Generation for Liver Cancer Research,” Cancer Letters 508 (2021): 13–17.

[42] W. L. Septiana, A. Noviantari, and R. D. Antarianto, “Induced Pluripotent Stem Cells (ipscs) Based Liver Organoid: The Benefits and Challenges,” Cell Physiol Biochem Int J Exp Cell Physiol Biochem Pharmacol 57, no. 5 (2023): 345–359.

[43] R. Guo, Y. Chen, J. Zhang, et al., “Neural Differentiation and Spinal Cord Organoid Generation From Induced Pluripotent Stem Cells (iPSCs) for ALS Modelling and Inflammatory Screening,” Molecular Neurobiology 61, no. 7 (2024): 4732–4749.

[44] F. Blokzijl, J. de Ligt, M. Jager, et al., “Tissue-specific Mutation Accumulation in human Adult Stem Cells During Life,” Nature 538, no. 7624 (2016): 260–264.

[45] L. Broutier, G. Mastrogiovanni, M. M. Verstegen, et al., “Human Primary Liver Cancer–derived Organoid Cultures for Disease Modeling and Drug Screening,” Nature Medicine 23, no. 12 (2017): 1424–1435.

[46] D. Hendriks, J. F. Brouwers, K. Hamer, et al., “Engineered human Hepatocyte Organoids Enable CRISPR-based Target Discovery and Drug Screening for Steatosis,” Nature Biotechnology 41, no. 11 (2023): 1567–1581.

[47] N. Tanimizu, N. Ichinohe, Y. Sasaki, et al., “Generation of Functional Liver Organoids on Combining Hepatocytes and Cholangiocytes With Hepatobiliary Connections Ex Vivo,” Nature Communications 12, no. 1 (2021): 3390.

[48] H. F. Farin, J. H. V. Es, and H. Clevers, “Redundant Sources of Wnt Regulate Intestinal Stem Cells and Promote Formation of Paneth Cells,” Gastroenterology 143, no. 6 (2012): 1518–1529. e7.

[49] H. Esser, A. M. Kilpatrick, T. Y. Man, et al., “Primary Cilia as a Targetable Node Between Biliary Injury, Senescence and Regeneration in Liver Transplantation,” Journal of Hepatology 81, no. 6 (2024): 1005–1022. Published online June. S016882782402302X.

[50] J. Liu, P. Li, L. Wang, et al., “Cancer-Associated Fibroblasts Provide a Stromal Niche for Liver Cancer Organoids That Confers Trophic Effects and Therapy Resistance,” Cell Mol Gastroenterol Hepatol 11, no. 2 (2021): 407–431.

[51] L. Sun, Y. Wang, J. Cen, et al., “Modelling Liver Cancer Initiation With Organoids Derived From Directly Reprogrammed human Hepatocytes,” Nature Cell Biology 21, no. 8 (2019): 1015–1026.

[52] H. S. Lee, D. H. Han, K. Cho, et al., “Integrative Analysis of Multiple Genomic Data From Intrahepatic Cholangiocarcinoma Organoids Enables Tumor Subtyping,” Nature Communications 14, no. 1 (2023): 237.

[53] M. M. A. Verstegen, F. J. M. Roos, K. Burka, et al., “Human Extrahepatic and Intrahepatic Cholangiocyte Organoids Show Region-specific Differentiation Potential and Model Cystic Fibrosis-related Bile Duct Disease,” Scientific Reports 10, no. 1 (2020): 21900.

[54] F. Sampaziotis, M. Cardoso De Brito, and P. Madrigal, “Cholangiocytes Derived From human Induced Pluripotent Stem Cells for Disease Modeling and Drug Validation,” Nature Biotechnology 33, no. 8 (2015): 845–852.

[55] M. Huch, C. Dorrell, S. F. Boj, et al., “In Vitro Expansion of Single Lgr5+ Liver Stem Cells Induced by Wnt-driven Regeneration,” Nature 494, no. 7436 (2013): 247–250.

[56] H. Koike, K. Iwasawa, R. Ouchi, et al., “Engineering human Hepato-biliary-pancreatic Organoids From Pluripotent Stem Cells,” Nature Protocols 16, no. 2 (2021): 919–936.

[57] T. Takebe, K. Sekine, M. Enomura, et al., “Vascularized and Functional human Liver From an iPSC-derived Organ Bud Transplant,” Nature 499, no. 7459 (2013): 481–484.

[58] R. Ouchi, S. Togo, M. Kimura, et al., “Modeling Steatohepatitis in Humans With Pluripotent Stem Cell-Derived Organoids,” Cell Metabolism 30, no. 2 (2019): 374–384. e6.

[59] K. W. McCracken, E. M. Catá, C. M. Crawford, et al., “Modelling human Development and Disease in Pluripotent Stem-cell-derived Gastric Organoids,” Nature 516, no. 7531 (2014): 400–404.

[60] S. Bartfeld, T. Bayram, M. van de Wetering, et al., “In Vitro Expansion of human Gastric Epithelial Stem Cells and Their Responses to Bacterial Infection,” Gastroenterology 148, no. 1 (2015): 126–136. e6.

[61] M. Huch, P. Bonfanti, S. F. Boj, et al., “Unlimited in Vitro Expansion of Adult bi-potent Pancreas Progenitors Through the Lgr5/R-spondin Axis,” Embo Journal 32, no. 20 (2013): 2708–2721.

[62] C. Dorrell, B. Tarlow, Y. Wang, et al., “The Organoid-initiating Cells in Mouse Pancreas and Liver Are Phenotypically and Functionally Similar,” Stem Cell Res 13, no. 2 (2014): 275–283.

[63] F. Sampaziotis, M. C. de Brito, I. Geti, A. Bertero, N. R. Hannan, and L. Vallier, “Directed Differentiation of human Induced Pluripotent Stem Cells Into Functional Cholangiocyte-Like Cells,” Nature Protocols 12, no. 4 (2017): 814–827.

[64] F. Sampaziotis. Directed differentiation of human induced pluripotent stem cells into functional cholangiocyte-like cells. Published online 2017.

[65] J. R. Spence, C. N. Mayhew, S. A. Rankin, et al., “Directed Differentiation of human Pluripotent Stem Cells Into Intestinal Tissue in Vitro,” Nature 470, no. 7332 (2011): 105–109.

[66] T. Sato, D. E. Stange, M. Ferrante, et al., “Long-term Expansion of Epithelial Organoids from Human Colon, Adenoma, Adenocarcinoma, and Barrett's Epithelium,” Gastroenterology 141, no. 5 (2011): 1762–1772.

[67] T. Sato and H. Clevers, “Growing Self-Organizing Mini-Guts From a Single Intestinal Stem Cell: Mechanism and Applications,” Science 340, no. 6137 (2013): 1190–1194.

[68] T. Sato, R. G. Vries, H. J. Snippert, et al., “Single Lgr5 Stem Cells Build Crypt-villus Structures in Vitro Without a Mesenchymal Niche,” Nature 459, no. 7244 (2009): 262–265.

[69] P. Jung, T. Sato, A. Merlos-Suárez, et al., “Isolation and in Vitro Expansion of human Colonic Stem Cells,” Nature Medicine 17, no. 10 (2011): 1225–1227.

[70] W. de Lau, P. Kujala, K. Schneeberger, et al., “Peyer's Patch M Cells Derived From Lgr5(+) Stem Cells Require SpiB and Are Induced by RankL in Cultured “Miniguts”,” Molecular and Cellular Biology 32, no. 18 (2012): 3639–3647.

[71] M. Takasato, P. X. Er, H. S. Chiu, and M. H. Little, “Generation of Kidney Organoids From human Pluripotent Stem Cells,” Nature Protocols 11, no. 9 (2016): 1681–1692.

[72] M. Takasato, P. X. Er, H. S. Chiu, et al., “Kidney Organoids From human iPS Cells Contain Multiple Lineages and Model human Nephrogenesis,” Nature 526, no. 7574 (2015):564–568.

[73] S. I. Mae, A. Shono, F. Shiota, et al., “Monitoring and Robust Induction of Nephrogenic Intermediate Mesoderm From human Pluripotent Stem Cells,” Nature Communications 4 (2013): 1367.

[74] K. A. Homan, N. Gupta, K. T. Kroll, et al., “Flow-enhanced Vascularization and Maturation of Kidney Organoids in Vitro,” Nature Methods 16, no. 3 (2019): 255–262.

[75] S. F. Boj, C. I. Hwang, L. A. Baker, et al., “Organoid Models of Human and Mouse Ductal Pancreatic Cancer,” Cell 160, no. 1-2 (2015): 324–338.

[76] J. F. Dekkers, C. L. Wiegerinck, and H. R. de Jonge, “A Functional CFTR Assay Using Primary Cystic Fibrosis Intestinal Organoids,” Nature Medicine 19, no. 7 (2013): 939–945.

[77] M. Krüger, L. A. Oosterhoff, M. E. Van Wolferen, et al., “Cellulose Nanofibril Hydrogel Promotes Hepatic Differentiation of Human Liver Organoids,” Adv Healthc Mater 9, no. 6 (2020): 1901658.

[78] M. T. Kozlowski, C. J. Crook, and H. T. Ku, “Towards Organoid Culture Without Matrigel,” Communications Biology 4, no. 1 (2021): 1387.

[79] A. J. Engler, S. Sen, H. L. Sweeney, and D. E. Discher, “Matrix Elasticity Directs Stem Cell Lineage Specification,” Cell 126, no. 4 (2006): 677–689.

[80] S. Dahl-Jensen and A. Grapin-Botton, “The Physics of Organoids: A Biophysical Approach to Understanding Organogenesis,” Dev Camb Engl 144, no. 6 (2017): 946–951.

[81] C. M. Nelson and J. P. Gleghorn, “Sculpting Organs: Mechanical Regulation of Tissue Development,” Annual Review of Biomedical Engineering 14 (2012): 129–154.

[82] W. L. Murphy, T. C. McDevitt, and A. J. Engler, “Materials as Stem Cell Regulators,” Nature Materials 13, no. 6 (2014): 547–557.

[83] K. H. Vining and D. J. Mooney, “Mechanical Forces Direct Stem Cell Behaviour in Development and Regeneration,” Nature Reviews Molecular Cell Biology 18, no. 12 (2017): 728–742.

[84] G. Benton, J. George, H. K. Kleinman, and I. P. Arnaoutova, “Advancing Science and Technology via 3D Culture on Basement Membrane Matrix,” Journal of Cellular Physiology 221, no. 1 (2009): 18–25.

[85] Y. R. Lou, L. Kanninen, T. Kuisma, et al., “The Use of Nanofibrillar Cellulose Hydrogel as a Flexible Three-dimensional Model to Culture human Pluripotent Stem Cells,” Stem Cells and Development 23, no. 4 (2014): 380–392.

[86] H. K. Kleinman and G. R. Martin, “Matrigel: Basement Membrane Matrix With Biological Activity,” Seminars in Cancer Biology 15, no. 5 (2005): 378–386.

[87] S. Vukicevic, H. K. Kleinman, F. P. Luyten, A. B. Roberts, N. S. Roche, and A. H. Reddi, “Identification of Multiple Active Growth Factors in Basement Membrane Matrigel Suggests Caution in Interpretation of Cellular Activity Related to Extracellular Matrix Components,” Experimental Cell Research 202, no. 1 (1992): 1–8.

[88] C. S. Hughes, L. M. Postovit, and G. A. Lajoie, “Matrigel: A Complex Protein Mixture Required for Optimal Growth of Cell Culture,” Proteomics 10, no. 9 (2010): 1886–1890.

[89] S. Ye, J. W. B. Boeter, M. Mihajlovic, et al., “A Chemically Defined Hydrogel for Human Liver Organoid Culture,” Advanced Functional Materials 30, no. 48 (2020): 2000893.

[90] G. Benton, I. Arnaoutova, J. George, H. K. Kleinman, and K. J. Matrigel, “From Discovery and ECM Mimicry to Assays and Models for Cancer Research,” Advanced Drug Delivery Reviews (2014): 79–80. 3-18.

[91] E. Garreta, R. D. Kamm, S. M. Chuva De Sousa Lopes, et al., “Rethinking Organoid Technology Through Bioengineering,” Nature Materials 20, no. 2 (2021): 145–155.

[92] S. Ye, J. W. B. Boeter, L. C. Penning, B. Spee, and K. Schneeberger, “Hydrogels for Liver Tissue Engineering,” Bioeng Basel Switz 6, no. 3 (2019): 59.

[93] Y. Hu and J. M. Catchmark, “Integration of Cellulases Into Bacterial Cellulose: Toward Bioabsorbable Cellulose Composites,” Journal of Biomedical Materials Research Part B, Applied Biomaterials 97, no. 1 (2011): 114–123.

[94] M. Krueger, L. Oosterhoff, M. Wolferen, et al., “Cellulose Nanofibril Hydrogel Promotes Hepatic Differentiation of human Liver Organoids,” Adv Healthc Mater 9 (2020): 1901658.

[95] R. Cruz-Acuña, M. Quirós, A. E. Farkas, et al., “Synthetic Hydrogels for human Intestinal Organoid Generation and Colonic Wound Repair,” Nature Cell Biology 19, no. 11 (2017): 1326–1335.

[96] N. Gjorevski, N. Sachs, A. Manfrin, et al., “Designer Matrices for Intestinal Stem Cell and Organoid Culture,” Nature 539, no. 7630 (2016): 560–564.

[97] Z. Gan, X. Qin, H. Liu, J. Liu, and J. Qin, “Recent Advances in Defined Hydrogels in Organoid Research,” Bioact Mater 28 (2023): 386–401.

[98] G. Sorrentino, S. Rezakhani, E. Yildiz, et al., “Mechano-modulatory Synthetic Niches for Liver Organoid Derivation,” Nature Communications 11, no. 1 (2020): 3416.

[99] Y. Wang, H. Liu, M. Zhang, H. Wang, W. Chen, and J. Qin, “One-step Synthesis of Composite Hydrogel Capsules to Support Liver Organoid Generation From hiPSCs,” Biomater Sci 8, no. 19 (2020): 5476–5488.

[100] B. E. Uygun, A. Soto-Gutierrez, H. Yagi, et al., “Organ Reengineering Through Development of a Transplantable Recellularized Liver Graft Using Decellularized Liver Matrix,” Nature Medicine 16, no. 7 (2010): 814–820.

[101] J. Willemse, G. van Tienderen, E. van Hengel, et al., “Hydrogels Derived From Decellularized Liver Tissue Support the Growth and Differentiation of Cholangiocyte Organoids,” Biomaterials 284 (2022): 121473.

[102] J. Puschhof, C. Pleguezuelos-Manzano, A. Martinez-Silgado, et al., “Intestinal Organoid Cocultures With Microbes,” Nature Protocols 16, no. 10 (2021): 4633–4649.

[103] H. Han, T. Zhan, N. Guo, M. Cui, and Y. Xu, “Cryopreservation of Organoids: Strategies, Innovation, and Future Prospects,” Biotechnology Journal 19, no. 2 (2024): 2300543.

[104] J. M. Vega H. de, H. J. Hong, K. Loutherback, G. Stybayeva, and A. Revzin, “A Microfluidic Device for Long-term Maintenance of Organotypic Liver Cultures,” Advanced Materials Technology 8, no. 2 (2023): 2201121.

[105] M. Huch, C. Dorrell, S. F. Boj, et al., “In Vitro Expansion of Single Lgr5+ Liver Stem Cells Induced by Wnt-driven Regeneration,” Nature 494, no. 7436 (2013): 247–250.

[106] V. Padmanaban, E. M. Grasset, N. M. Neumann, et al., “Organotypic Culture Assays for Murine and human Primary and Metastatic-site Tumors,” Nature Protocols 15, no. 8 (2020): 2413–2442.

[107] L. Aloia, M. A. McKie, G. Vernaz, et al., “Epigenetic Remodelling Licences Adult Cholangiocytes for Organoid Formation and Liver Regeneration,” Nature Cell Biology 21, no. 11 (2019): 1321–1333.

[108] F. Schutgens, M. B. Rookmaaker, T. Margaritis, et al., “Tubuloids Derived From human Adult Kidney and Urine for Personalized Disease Modeling,” Nature Biotechnology 37, no. 3 (2019): 303–313.

[109] N. Sachs, J. de Ligt, O. Kopper, et al., “A Living Biobank of Breast Cancer Organoids Captures Disease Heterogeneity,” Cell 172, no. 1-2 (2018): 373–386. e10.

[110] F. Clotman, P. Jacquemin, N. Plumb-Rudewiez, et al., “Control of Liver Cell Fate Decision by a Gradient of TGF Beta Signaling Modulated by Onecut Transcription Factors,” Genes & Development 19, no. 16 (2005): 1849–1854.

[111] M. Yanai, N. Tatsumi, N. Hasunuma, K. Katsu, F. Endo, and Y. Yokouchi, “FGF Signaling Segregates Biliary Cell-lineage From Chick Hepatoblasts Cooperatively With BMP4 and ECM Components in Vitro,” Dev Dyn Off Publ Am Assoc Anat 237, no. 5 (2008): 1268–1283.

[112] J. H. Tabibian, C. E. Trussoni, S. P. O'Hara, P. L. Splinter, J. K. Heimbach, and N. F. LaRusso, “Characterization of Cultured Cholangiocytes Isolated From Livers of Patients With Primary Sclerosing Cholangitis,” Lab Investig J Tech Methods Pathol 94, no. 10 (2014): 1126–1133.

[113] S. Raghavan, P. S. Winter, A. W. Navia, et al., “Microenvironment Drives Cell state, Plasticity, and Drug Response in Pancreatic Cancer,” Cell 184, no. 25 (2021): 6119–6137. e26.

[114] D. Hendriks, B. Artegiani, T. Margaritis, I. Zoutendijk, S. Chuva De Sousa Lopes, and H. Clevers, “Mapping of Mitogen and Metabolic Sensitivity in Organoids Defines Requirements for human Hepatocyte Growth,” Nature Communications 15, no. 1 (2024): 4034.

[115] H. Wu, J. Wang, S. Liu, et al., “Large-scale Production of Expandable Hepatoblast Organoids and Polarised Hepatocyte Organoids From <Span Style = “Font-variant:Small-caps;”>hESCs</Span> Under 3D Static and Dynamic Suspension Conditions,” Cell Proliferation 58, no. 7 (2025): e70001.

[116] T. Utami, M. Danoy, R. R. Khadim, et al., “A Highly Efficient Cell Culture Method Using Oxygen-permeable PDMS-based Honeycomb Microwells Produces Functional Liver Organoids From human Induced Pluripotent Stem Cell-derived Carboxypeptidase M Liver Progenitor Cells,” Biotechnology and Bioengineering 121, no. 4 (2024): 1177–1189.

[117] H. Wu, A. S. P. Yang, S. Stelloo, et al., “Multi-omics Analysis Reveals Distinct Gene Regulatory Mechanisms Between Primary and Organoid-derived human Hepatocytes,” Disease Models & Mechanisms 18, no. 1 (2025): dmm050883.

[118] A. Messina, E. Luce, N. Benzoubir, et al., “Evidence of Adult Features and Functions of Hepatocytes Differentiated From human Induced Pluripotent Stem Cells and Self-organized as Organoids,” Cells 11, no. 3 (2022): 537.

[119] S. Jiang, F. Xu, and M. Jin, “Development of a High-throughput Micropatterned Agarose Scaffold for Consistent and Reproducible hPSC-derived Liver Organoids,” Biofabrication 15, no. 1 (2023): 015006.

[120] X. Xu, S. Jiang, L. Gu, et al., “High-throughput Bioengineering of Homogenous and Functional human-induced Pluripotent Stem Cells-derived Liver Organoids via Micropatterning Technique,” Frontiers in Bioengineering and Biotechnology 10 (2022): 937595.

[121] B. S. Elci, M. Nikolaev, S. Rezakhani, and M. P. Lutolf, “Bioengineered Tubular Biliary Organoids,” Adv Healthc Mater 13, no. 8 (2024): 2302912.

[122] S. P. Harrison, R. Siller, Y. Tanaka, et al., “Scalable Production of Tissue-Like Vascularized Liver Organoids From human PSCs,” Experimental & Molecular Medicine 55, no. 9 (2023): 2005–2024.

[123] D. Hendriks, B. Artegiani, H. Hu, S. Chuva De Sousa Lopes, and H. Clevers, “Establishment of human Fetal Hepatocyte Organoids and CRISPR–Cas9-based Gene Knockin and Knockout in Organoid Cultures From human Liver,” Nature Protocols 16, no. 1 (2021): 182–217.

[124] J. F. Dekkers, M. Alieva, L. M. Wellens, et al., “High-resolution 3D Imaging of Fixed and Cleared Organoids,” Nature Protocols 14, no. 6 (2019): 1756–1771.

[125] A. L. Gonzalez, A. Luciana, C. Le Nevé, et al., “Staining and High-resolution Imaging of Three-dimensional Organoid and Spheroid Models,” JoVE J Vis Exp no. 169 (2021): e62280.

[126] V. Korinek, N. Barker, P. Moerer, et al., “Depletion of Epithelial Stem-cell Compartments in the Small Intestine of Mice Lacking Tcf-4,” Nature Genetics 19, no. 4 (1998): 379–383.

[127] D. Pinto, A. Gregorieff, H. Begthel, and H. Clevers, “Canonical Wnt Signals Are Essential for Homeostasis of the Intestinal Epithelium,” Genes & Development 17, no. 14 (2003): 1709–1713.

[128] F. Kuhnert, C. R. Davis, H. T. Wang, et al., “Essential Requirement for Wnt Signaling in Proliferation of Adult Small Intestine and Colon Revealed by Adenoviral Expression of Dickkopf-1,” PNAS 101, no. 1 (2004): 266–271.

[129] H. Clevers, “The Intestinal Crypt, a Prototype Stem Cell Compartment,” Cell 154, no. 2 (2013): 274–284.

[130] F. J. M. Roos, H. Wu, J. Willemse, et al., “Cholangiocyte Organoids From human Bile Retain a Local Phenotype and Can Repopulate Bile Ducts in Vitro,” Clinical and Translational Medicine 11, no. 12 (2021): e566.

[131] B. Phipson, P. X. Er, A. N. Combes, et al., “Evaluation of Variability in human Kidney Organoids,” Nature Methods 16, no. 1 (2019): 79–87.

[132] J. O. R. Hernandez, X. Wang, M. Vazquez-Segoviano, et al., “A Tissue-bioengineering Strategy for Modeling Rare human Kidney Diseases in Vivo,” Nature Communications 12, no. 1 (2021): 6496.

[133] R. Morizane, A. Q. Lam, B. S. Freedman, S. Kishi, M. T. Valerius, and J. V. Bonventre, “Nephron Organoids Derived From human Pluripotent Stem Cells Model Kidney Development and Injury,” Nature Biotechnology 33, no. 11 (2015): 1193–1200.

[134] G. Obaid, S. Bano, S. Mallidi, et al., “Impacting Pancreatic Cancer Therapy in Heterotypic in Vitro Organoids and in Vivo Tumors With Specificity-Tuned, NIR-Activable Photoimmunonanoconjugates: Towards Conquering Desmoplasia?,” Nano Letters 19, no. 11 (2019): 7573–7587.

[135] T. Conroy, F. Desseigne, M. Ychou, et al., “FOLFIRINOX versus gemcitabine for Metastatic Pancreatic Cancer,” New England Journal of Medicine 364, no. 19 (2011): 1817–1825.

[136] D. P. Ryan, T. S. Hong, and N. Bardeesy, “Pancreatic adenocarcinoma,” New England Journal of Medicine 371, no. 22 (2014): 2140–2141.

[137] A. A. Khorana, P. B. Mangu, J. Berlin, et al., “Potentially Curable Pancreatic Cancer: American society of clinical oncology clinical practice Guideline,” J Clin Oncol Off J Am Soc Clin Oncol 34, no. 21 (2016): 2541–2556.

[138] J. M. Winter, J. L. Cameron, K. A. Campbell, et al., “1423 pancreaticoduodenectomies for Pancreatic Cancer: A Single-institution Experience,” J Gastrointest Surg Off J Soc Surg Aliment Tract 10, no. 9 (2006): 1210–1211.

[139] H. Tiriac, J. C. Bucobo, D. Tzimas, et al., “Successful Creation of Pancreatic Cancer Organoids by Means of EUS-guided Fine-needle Biopsy Sampling for Personalized Cancer Treatment,” Gastrointestinal Endoscopy 87, no. 6 (2018): 1474–1480.

[140] H. Tiriac, P. Belleau, D. D. Engle, et al., “Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer,” Cancer Discovery 8, no. 9 (2018): 1112–1129.

[141] M. E. Gilles, L. Hao, L. Huang, et al., “Personalized RNA Medicine for Pancreatic Cancer,” Clinical Cancer Research 24, no. 7 (2018): 1734–1747.

[142] T. Sato, J. H. Van Es, H. J. Snippert, et al., “Paneth Cells Constitute the Niche for Lgr5 Stem Cells in Intestinal Crypts,” Nature 469, no. 7330 (2011): 415–418.

[143] L. Broutier, A. Andersson-Rolf, C. J. Hindley, et al., “Culture and Establishment of Self-renewing human and Mouse Adult Liver and Pancreas 3D Organoids and Their Genetic Manipulation,” Nature Protocols 11, no. 9 (2016): 1724–1743.

[144] M. Nikolaev, O. Mitrofanova, N. Broguiere, et al., “Homeostatic Mini-intestines Through Scaffold-guided Organoid Morphogenesis,” Nature 585, no. 7826 (2020): 574–578.

[145] J. P. Licata, K. H. Schwab, H.-E. Y. el, J. A. Gerstenhaber, and P. I. Lelkes, “Bioreactor Technologies for Enhanced Organoid Culture,” International Journal of Molecular Sciences 24, no. 14 (2023): 11427.

[146] S. Ye, A. Marsee, G. S. van Tienderen, et al., “Accelerated Production of human Epithelial Organoids in a Miniaturized Spinning Bioreactor,” Cell Reports Methods 4, no. 11 (2024): 100903.

[147] J. P. Licata, J. A. Gerstenhaber, and P. I. Lelkes, “Novel, Low-cost Bioreactor for in Vitro Electrical Stimulation of Cardiac Cells,” Frontiers in Bioengineering and Biotechnology 13 (2025).

[148] L. Sassi, O. Ajayi, S. Campinoti, et al., “A Perfusion Bioreactor for Longitudinal Monitoring of Bioengineered Liver Constructs,” Nanomaterials 11, no. 2 (2021): 275.

[149] X. Qian, F. Jacob, M. M. Song, H. N. Nguyen, H. Song, and G. L. Ming, “Generation of human Brain Region–specific Organoids Using a Miniaturized Spinning Bioreactor,” Nature Protocols 13, no. 3 (2018): 565–580.

[150] G. Saorin, I. Caligiuri, and F. Rizzolio, “Microfluidic Organoids-on-a-chip: The Future of human Models,” Seminars in Cell & Developmental Biology 144 (2023): 41–54.

[151] L. Papamichail, L. S. Koch, D. Veerman, K. Broersen, and A. D. van der Meer, “Organoids-on-a-chip: Microfluidic Technology Enables Culture of Organoids With Enhanced Tissue Function and Potential for Disease Modeling,” Frontiers in Bioengineering and Biotechnology 13 (2025).

[152] C. Quintard, E. Tubbs, G. Jonsson, et al., “A Microfluidic Platform Integrating Functional Vascularized Organoids-on-chip,” Nature Communications 15, no. 1 (2024): 1452.

[153] F. Tomatis, S. Angiolillo, E. Maniou, O. Gagliano, and N. Elvassore, “Microfluidic Platforms for Organ-on-a-chip Models: Creating Dynamic Microenvironments for Organoid and Multi-organ Systems,” Curr Opin Biomed Eng (2025): 100630. Published online November 3.

[154] R. Novak, M. Ingram, S. Clauson, et al., “A Robotic Platform for Fluidically-linked human Body-on-chips Experimentation,” Nature Biomedical Engineering 4, no. 4 (2020): 407–420.

[155] R. Novak, M. Ingram, S. Marquez, et al., “Robotic Fluidic Coupling and Interrogation of Multiple Vascularized Organ Chips,” Nature Biomedical Engineering 4, no. 4 (2020): 407–420.

[156] J. Ko, S. Hyung, S. Cheong, Y. Chung, and N. Li Jeon, “Revealing the Clinical Potential of High-resolution Organoids,” Advanced Drug Delivery Reviews 207 (2024): 115202.

[157] M. J. Lee, J. Lee, J. Ha, et al., “Long-term Three-dimensional High-resolution Imaging of Live Unlabeled Small Intestinal Organoids via Low-coherence Holotomography,” Experimental & Molecular Medicine (2024): 1–9. Published online October 1.

[158] Y. Kang, J. Deng, J. Ling, et al., “3D imaging Analysis on an Organoid-based Platform Guides Personalized Treatment in Pancreatic Ductal Adenocarcinoma,” Journal of Clinical Investigation 132, no. 24 (2022): e151604.

[159] A. Chen, W. Wang, Z. Mao, et al., “Multimaterial 3D and 4D Bioprinting of Heterogenous Constructs for Tissue Engineering,” Adv Mater Deerfield Beach Fla 36, no. 34 (2024): e2307686.

[160] M. Chadwick, C. Yang, L. Liu, et al., “Rapid Processing and Drug Evaluation in Glioblastoma Patient-Derived Organoid Models With 4D Bioprinted Arrays,” Iscience 23, no. 8 (2020): 101365.

[161] S. Miao, W. Zhu, N. J. Castro, et al., “4D printing Smart Biomedical Scaffolds With Novel Soybean Oil Epoxidized Acrylate,” Scientific Reports 6, no. 1 (2016): 27226.

[162] A. S. Gladman, E. A. Matsumoto, R. G. Nuzzo, L. Mahadevan, and J. A. Lewis, “Biomimetic 4D Printing,” Nature Materials 15, no. 4 (2016): 413–418.

[163] B. Gao, Q. Yang, X. Zhao, G. Jin, Y. Ma, and F. Xu, “4D bioprinting for Biomedical Applications,” Trends in Biotechnology 34, no. 9 (2016): 746–756.

[164] K. Yuki, N. Cheng, M. Nakano, and C. J. Kuo, “Organoid Models of Tumor Immunology,” Trends in Immunology 41, no. 8 (2020): 652–664.

[165] E. Carolina, Y. Kuse, A. Okumura, et al., “Generation of human iPSC-derived 3D Bile Duct Within Liver Organoid by Incorporating human iPSC-derived Blood Vessel,” Nature Communications 15, no. 1 (2024): 7424.

[166] N. Nakamoto, N. Sasaki, R. Aoki, et al., “Gut Pathobionts Underlie Intestinal Barrier Dysfunction and Liver T Helper 17 Cell Immune Response in Primary Sclerosing Cholangitis,” Nature Microbiology 4, no. 3 (2019): 492–503.

[167] H. Koike, K. Iwasawa, R. Ouchi, et al., “Modelling human Hepato-biliary-pancreatic Organogenesis From the Foregut–midgut Boundary,” Nature 574, no. 7776 (2019): 112–116.

[168] Y. S. Zhang, J. Aleman, S. R. Shin, et al., “Multisensor-integrated Organs-on-chips Platform for Automated and Continual in Situ Monitoring of Organoid Behaviors,” Pnas 114, no. 12 (2017): E2293–E2302.

[169] A. Skardal, S. V. Murphy, M. Devarasetty, et al., “Multi-tissue Interactions in an Integrated Three-tissue Organ-on-a-chip Platform,” Scientific Reports 7, no. 1 (2017): 8837.

[170] T. Shinozawa, M. Kimura, Y. Cai, et al., “High-Fidelity Drug-Induced Liver Injury Screen Using Human Pluripotent Stem Cell–Derived Organoids,” Gastroenterology 160, no. 3 (2021): 831–846. e10.

[171] A. A. Qureshi, C. J. Wehrle, S. Ferreira-Gonzalez, et al., “Tumor Organoids for Primary Liver Cancers: A Systematic Review of Current Applications in Diagnostics, Disease Modeling, and Drug Screening,” JHEP Rep Innov Hepatol 6, no. 12 (2024): 101164.

[172] H. Jin, Q. Yang, J. Yang, et al., “Exploring Tumor Organoids for Cancer Treatment,” APL Materials 12 (2024): 060602.

[173] Q. Yang, M. Li, Z. Xiao, Y. Feng, L. Lei, and S. Li, “A New Perspective on Precision Medicine: The Power of Digital Organoids,” Biomater Res 29 (2025): 0171.

[174] Y. Li, P. Tang, S. Cai, J. Peng, and G. Hua, “Organoid Based Personalized Medicine: From Bench to Bedside,” Cell Regen 9, no. 1 (2020): 21.

[175] E. De Crignis, T. Hossain, S. Romal, et al., “Application of human Liver Organoids as a Patient-derived Primary Model for HBV Infection and Related Hepatocellular Carcinoma,” Elife 10 (2021): e60747.

[176] P. Kreiner, E. Eggenhofer, L. Schneider, et al., “Extrahepatic Bile Duct Organoids as a Model to Study Ischemia/Reperfusion Injury During Liver Transplantation,” Transplant International 37 (2024): 13212.

[177] H. Jin, Z. Xue, J. Liu, B. Ma, J. Yang, and L. Lei, “Advancing Organoid Engineering for Tissue Regeneration and Biofunctional Reconstruction,” Biomater Res 28 (2024): 0016. Published online April 15.

[178] S. Yui, T. Nakamura, T. Sato, et al., “Functional Engraftment of Colon Epithelium Expanded in Vitro From a Single Adult Lgr5+ Stem Cell,” Nature Medicine 18, no. 4 (2012): 618–623.

[179] W. C. Peng, C. Y. Logan, M. Fish, et al., “Inflammatory Cytokine TNFα Promotes the Long-term Expansion of Primary Hepatocytes in 3D Culture,” Cell 175, no. 6 (2018): 1607–1619. e15.

[180] H. Hu, H. Gehart, B. Artegiani, et al., “Long-term Expansion of Functional Mouse and human Hepatocytes as 3D Organoids,” Cell 175, no. 6 (2018): 1591–1606. e19.

[181] W. Y. Lu, T. G. Bird, L. Boulter, et al., “Hepatic Progenitor Cells of Biliary Origin With Liver Repopulation Capacity,” Nature Cell Biology 17, no. 8 (2015): 971–983.

[182] F. Sampaziotis, D. Muraro, O. C. Tysoe, et al., “Cholangiocyte Organoids Can Repair Bile Ducts After Transplantation in the human Liver,” Science 371, no. 6531 (2021): 839–846.

[183] E. Yoshihara, C. O'Connor, and E. Gasser, “Immune-evasive human Islet-Like Organoids Ameliorate Diabetes,” Nature 586, no. 7830 (2020): 606–611.

[184] A. Marsee, F. J. M. Roos, M. M. A. Verstegen, et al., “Building Consensus on Definition and Nomenclature of Hepatic, Pancreatic, and Biliary Organoids,” Cell Stem Cell 28, no. 5 (2021): 816–832.

[185] P. N. Bernal, M. Bouwmeester, J. Madrid-Wolff, et al., “Volumetric Bioprinting of Organoids and Optically Tuned Hydrogels to Build Liver-Like Metabolic Biofactories,” Advanced Materials 34, no. 15 (2022): 2110054.

[186] S. Shrestha, V. K. R. Lekkala, P. Acharya, S. Y. Kang, M. G. Vanga, and M. Y. Lee, “Reproducible Generation of human Liver Organoids (HLOs) on a Pillar Plate Platform via Microarray 3D Bioprinting,” Lab on A Chip 24, no. 10 (2024): 2747–2761.

[187] S. Abbasalizadeh, S. Babaee, R. Kowsari-Esfahan, et al., “Continuous Production of Highly Functional Vascularized Hepatobiliary Organoids From human Pluripotent Stem Cells Using a Scalable Microfluidic Platform,” Advanced Functional Materials 33, no. 49 (2023): 2210233.

[188] A. Schlegel, H. Mergental, C. Fondevila, R. J. Porte, P. J. Friend, and P. Dutkowski, “Machine Perfusion of the Liver and Bioengineering,” Journal of Hepatology 78, no. 6 (2023): 1181–1198.

[189] L. Bai, Y. Wu, G. Li, W. Zhang, H. Zhang, and J. Su, “AI-enabled Organoids: Construction, Analysis, and Application,” Bioact Mater 31 (2024): 525–548.

[190] X. Du, Z. Chen, Q. Li, et al., “Organoids Revealed: Morphological Analysis of the Profound next Generation in-vitro Model With Artificial Intelligence,” Bio-Des Manuf 6, no. 3 (2023): 319–339.

[191] C. Seah and K. J. Brennand, “Pandemic city: Village-in-a-dish Unlocks Dynamic Genetic Effects in the Brain,” Cell Stem Cell 30, no. 3 (2023): 239–241.

[192] J. Zhou, C. Li, X. Liu, et al., “Infection of Bat and human Intestinal Organoids by SARS-CoV-2,” Nature Medicine 26, no. 7 (2020): 1077–1083.

[193] W. Zhang, L. Yu, J. Pan, et al., “Geometrically-engineered human Motor Assembloids-on-a-chip for Neuromuscular Interaction Readout and Hypoxia-driven Disease Modeling,” Nature Communications 16, no. 1 (2025): 8693.

[194] F. Schutgens and H. Clevers, “Human Organoids: Tools for Understanding Biology and Treating Diseases,” Annual Review of Pathology 15 (2020): 211–234.

[195] D. Abbey, S. Elwyn, N. J. Hand, K. Musunuru, and D. J. Rader, “Self-organizing human Induced Pluripotent Stem Cell Hepatocyte 3D Organoids Inform the Biology of the Pleiotropic TRIB1 Gene,” Hepatol Communicatios 4, no. 9 (2020): 1316.

[196] L. Zhang, X. Wang, X. Yang, et al., “Genome Engineering of Primary and Pluripotent Stem Cell-derived Hepatocytes for Modeling Liver Tumor Formation,” Biology 13, no. 9 (2024):684.

[197] J. Li, J. Chu, V. C. H. Lui, S. Chen, Y. Chen, and P. K. H. Tam, “Bioengineering Liver Organoids for Diseases Modelling and Transplantation,” Bioengineering 9, no. 12 (2022): 796.

[198] E. Luce, A. Messina, and J. C. Duclos-Vallée, “Hepatic Organoids as a Platform for Liver Disease Modeling and the Development of Novel Therapies,” Clinics and Research in Hepatology and Gastroenterology 49, no. 7 (2025): 102647.

[199] L. Wang, Y. Koui, K. Kanegae, et al., “Establishment of human Induced Pluripotent Stem Cell-derived Hepatobiliary Organoid With Bile Duct for Pharmaceutical Research Use,” Biomaterials 310 (2024): 122621.

[200] G. Vlachogiannis, S. Hedayat, A. Vatsiou, et al., “Patient-derived Organoids Model Treatment Response of Metastatic Gastrointestinal Cancers,” Science 359, no. 6378 (2018): 920–926.

[201] L. A. Low, C. Mummery, B. R. Berridge, C. P. Austin, and D. A. Tagle, “Organs-on-chips: Into the next Decade,” Nat Rev Drug Discovery 20, no. 5 (2021): 345–361.

[202] M. C. Bouwmeester, P. N. Bernal, L. A. Oosterhoff, et al., “Bioprinting of human Liver-derived Epithelial Organoids for Toxicity Studies,” Macromolecular Bioscience 21, no. 12 (2021): 2100327.

[203] A. A. Cross-Najafi, K. Farag, A. M. Chen, et al., “The Long Road to Develop Custom-built Livers: Current Status of 3D Liver Bioprinting,” Transplantation 108, no. 2 (2024): 357.

[204] W. Zhang, M. Zhang, Z. Xu, et al., “Human Forebrain Organoid-based Multi-omics Analyses of PCCB as a Schizophrenia Associated Gene Linked to GABAergic Pathways,” Nature Communications 14, no. 1 (2023): 5176.

[205] Y. Li, S. Tang, H. Wang, et al., “A Pancreatic Cancer Organoid Biobank Links Multi-omics Signatures to Therapeutic Response and Clinical Evaluation of statin Combination Therapy,” Cell Stem Cell 32, no. 9 (2025): 1369–1389. e14.

[206] M. Lassé, J. El Saghir, C. C. Berthier, et al., “An Integrated Organoid Omics Map Extends Modeling Potential of Kidney Disease,” Nature Communications 14, no. 1 (2023): 4903.

[207] Y. H. Lo, H. T. Horn, M. F. Huang, et al., “Large-scale CRISPR Screening in Primary human 3D Gastric Organoids Enables Comprehensive Dissection of Gene-drug Interactions,” Nature Communications 16, no. 1 (2025): 7566.

[208] B. S. Park, M. Lee, J. Kim, and T. Kim, “Perturbomics: CRISPR–cas Screening-based Functional Genomics Approach for Drug Target Discovery,” Experimental & Molecular Medicine 57, no. 7 (2025): 1443–1454.

[209] Y. Chao, Y. Xiang, J. Xiao, et al., “Organoid-based Single-cell Spatiotemporal Gene Expression Landscape of human Embryonic Development and Hematopoiesis,” Signal Transduct Target Ther 8, no. 1 (2023): 230.

[210] S. Ma, W. Wang, J. Zhou, et al., “Lamination-based Organoid Spatially Resolved Transcriptomics Technique for Primary Lung and Liver Organoid Characterization,” PNAS 121, no. 46 (2024): e2408939121.

[211] D. Kim, H. Lim, J. Youn, T. E. Park, and D. S. Kim, “Scalable Production of Uniform and Mature Organoids in a 3D Geometrically-engineered Permeable Membrane,” Nature Communications 15, no. 1 (2024): 9420.

[212] G. Narazaki, Y. Miura, S. D. Pavlov, et al., “Scalable Production of human Cortical Organoids Using a Biocompatible Polymer,” Nat Biomed Eng (2025): 1–9. Published online June 27.

[213] A. Chrisnandy and M. P. Lutolf, “An Extracellular Matrix Niche Secreted by Epithelial Cells Drives Intestinal Organoid Formation,” Developmental Cell (2025). Published online July 17.

[214] K. Li, Y. He, X. Jin, K. Jin, and J. Qian, “Reproducible Extracellular Matrices for Tumor Organoid Culture: Challenges and Opportunities,” Journal of translational medicine 23, no. 1 (2025): 497.

[215] P. Avena, L. Zavaglia, I. Casaburi, and V. Pezzi, “Perfusion Bioreactor Technology for Organoid and Tissue Culture: A Mini Review,” Onco 5, no. 2 (2025): 17.

RIGHTS & PERMISSIONS

2026 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.